Open AccessMajor Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy
Author(s) -
Press Richard D.
Publication year - 2010
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2010-0055
Subject(s) - medicine , tyrosine kinase , targeted therapy , cancer therapy , cancer , tyrosine kinase inhibitor , dasatinib , cancer research , oncology , receptor
This article examines the role of real‐time quantitative polymerase chain reaction testing of BCR‐ABL transcript levels to assess minimal residual disease and outcomes in patients with chronic myeloid leukemia.